Roth MKM Maintains Buy on Champions Oncology, Lowers Price Target to $7.5
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Scott Henry maintains a Buy rating on Champions Oncology (NASDAQ:CSBR) but lowers the price target from $9 to $7.5.
September 22, 2023 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Champions Oncology's price target has been lowered from $9 to $7.5 by Roth MKM, though the Buy rating is maintained.
The lowering of the price target by Roth MKM could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Buy rating indicates that the analyst still sees potential in the company, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100